Pharmaust Limited

PAA

PharmAust Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-10-05. The Company’s segments include Corporate and Research. The firm is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The firm's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The firm is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. The company is focused on starting Phase II/III clinical study of MPL. The company has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. The company is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.

Botanix Pharmaceuticals Ltd

BOT

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the business of researching and developing dermatology and antimicrobial products. The company is headquartered in Leederville, Western Australia. The firm is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. The company also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

BetaShares Australia 200 ETF

A200

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6041.2m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

BetaShares Global Sustainability Leaders ETF

ETHI

ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.